オプションチェーンは、GrowGenerationの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、GrowGenerationの市場センチメントを評価します。.

GrowGeneration (NASDAQ:GRWG) 株価情報, オプションチェーン

GrowGeneration

GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.

GrowGeneration Corp

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/06/30/final-trades-applied-materials-unitedhealth-mercado-libre.html">Halftime Report Final Trades</a>,&#8221; Jim Lebenthal at Cerity Partners named Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) <a href="https://www.benzinga.com/quote/AMAT/analyst-ratings">as his final trade.</a>
Supporting his view, Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating for Applied Materials on June 24, raising the price target from $200 to $220.
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>).
Lending support to his choice, JP Morgan analyst Lisa Gill maintained a UnitedHealth Group rating of Overweight on June 20 and raised the price target from $405 to $418.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joseph M. Terranova is a senior managing director for Virtus Investment Partners, named MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) as his final trade.
Supporting his choice, Susquehanna analyst James Friedman, on June 26, maintained a Positive rating for MercadoLibre and raised the price target from $ 2,840 to $ 2,975.
Price Action:
<ul class="wp-block-list">
<li>Applied Materials shares fell 0.1% to close at $183.07 on Monday.</li>
<li>UnitedHealth Group rose 0.9% to settle at $311.97 during the session.</li>
<li>MercadoLibre shares gained 2.1% to settle at $2,613.63 on Monday.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in">5 Stocks In The Spotlight: Wall Street&#8217;s Most Accurate Analysts Weigh In</a></li>
</ul>
Photo: Shutterstock

Long Ideas

News

Markets

Media

Trading Ideas

AMAT

MELI

MercadoLibre, Applied Materials And A Healthcare Stock On CNBC's 'Final Trades'

Real Estate

Safe and Green Development Says Two Sites Independently Appraised At Combined $9.9M

UBS analyst Myles Allsop downgrades Southern Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) from Buy to Neutral and announces $105 price target.

Downgrades

Price Target

Analyst Ratings

SCCO

UBS Downgrades Southern Copper to Neutral, Announces $105 Price Target

DUOT

Duos Technologies Joins Russell Microcap Index

Wolfe Research analyst Scott Group upgrades C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) from Peer Perform to Outperform.

Upgrades

CHRW

Wolfe Research Upgrades C.H. Robinson Worldwide to Outperform

Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $7.7, a high estimate of $11.00, and a low estimate of $5.00. Observing a 11.59% increase, the current average has risen from the previous average price target of $6.90. 
<img src="https://www.benzinga.com/files/images/story/2025/1751371490_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Taysha Gene Therapies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Taysha Gene Therapies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Taysha Gene Therapies compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Taysha Gene Therapies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Taysha Gene Therapies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TSHA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Taysha Gene Therapies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Taysha Gene Therapies: A Closer Look</h2>
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
<h3>Breaking Down Taysha Gene Therapies's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Taysha Gene Therapies's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -32.51% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -935.23%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Taysha Gene Therapies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -34.02%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Taysha Gene Therapies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -14.41%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Taysha Gene Therapies's debt-to-equity ratio surpasses industry norms, standing at 1.11. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TSHA

Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock

SNCR

Synchronoss Technologies Joins Russell 2000 Index

4 analysts have expressed a variety of opinions on New Fortress Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.62, a high estimate of $14.00, and a low estimate of $4.00. A 58.95% drop is evident in the current average compared to the previous average price target of $21.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1751371480_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive New Fortress Energy is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giuliano Bologna</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Buy</td>
<td>$8.50</td>
<td>-</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$4.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Ryan Levine</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to New Fortress Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of New Fortress Energy compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of New Fortress Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of New Fortress Energy's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NFE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on New Fortress Energy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering New Fortress Energy: A Closer Look</h2>
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals &amp; Infrastructure, and Ships. It generates the majority of its revenue from the Terminals &amp; Infrastructure segment.
<h3>Financial Milestones: New Fortress Energy's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining New Fortress Energy's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -30.7% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: New Fortress Energy's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -42.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -11.04%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): New Fortress Energy's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.55%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 5.51, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into New Fortress Energy Stock: Analyst Perspectives (4 Ratings)

Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $54.75, with a high estimate of $64.00 and a low estimate of $48.00. A decline of 18.28% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1751371470_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Lineage by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Craig Mailman</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$49.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Blaine Heck</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$48.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$50.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Caitlin Burrows</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$63.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Alex Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$49.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$59.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Nicholas Thillman</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$56.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$59.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lineage. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Lineage compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Lineage's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LINE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lineage analyst ratings.</a>
<h2>All You Need to Know About Lineage</h2>
Lineage Inc is a temperature-controlled warehouse real estate investment trust. It operates an interconnected global temperature-controlled warehouse network, comprising approximately millions of square feet across several warehouses predominantly located in densely populated critical-distribution markets across North America, Asia-Pacific, and Europe. The company's reportable segments are Global Warehousing, which utilizes the company's industrial real estate properties to provide temperature-controlled warehousing services to its customers, and Global Integrated Solutions, which complements Global Warehousing with specialized cold-chain services. Maximum revenue is generated from the Global Warehousing segment. Geographically, the company derives its key revenue from the United States.
<h3>Financial Insights: Lineage</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Lineage's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -2.71% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.15%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Lineage's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.02%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Lineage's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.01%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Lineage's debt-to-equity ratio is below the industry average. With a ratio of 0.83, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LINE

Beyond The Numbers: 12 Analysts Discuss Lineage Stock

WIIM

HOOD

Robinhood Markets shares are trading higher after Keybanc raised its price target on the stock from $60 to $110.

Across the recent three months, 10 analysts have shared their insights on Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $53.9, a high estimate of $64.00, and a low estimate of $45.00. This current average has decreased by 0.19% from the previous average price target of $54.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1751371462_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Ionis Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$64.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ionis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Ionis Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Ionis Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IONS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ionis Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Ionis Pharmaceuticals</h2>
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
<h3>Ionis Pharmaceuticals: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ionis Pharmaceuticals displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 10.14%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -111.64%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ionis Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -27.62%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Ionis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.05%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 2.96. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IONS

10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know

Ratings for Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) were provided by 22 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $67.82, with a high estimate of $110.00 and a low estimate of $40.00. This upward trend is evident, with the current average reflecting a 3.91% increase from the previous average price target of $65.27.
<img src="https://www.benzinga.com/files/images/story/2025/1751371445_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Robinhood Markets's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Markgraff</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Ed Engel</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Charles Bendit</td>
<td>Redburn Atlantic</td>
<td>Raises</td>
<td>Sell</td>
<td>$48.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$71.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$72.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$58.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Michael Leshock</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$70.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$76.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Robinhood Markets. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Robinhood Markets compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Robinhood Markets's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HOOD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Robinhood Markets analyst ratings.</a>
<h2>Discovering Robinhood Markets: A Closer Look</h2>
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fraud detection, derivatives, fractional shares, recurring investments, and others.
<h3>Breaking Down Robinhood Markets's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Robinhood Markets displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 50.0%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 36.25%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Robinhood Markets's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.22%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Robinhood Markets's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.25%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Robinhood Markets's debt-to-equity ratio is below the industry average at 1.14, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Robinhood Markets Stands With Analysts

In the latest quarter, 5 analysts provided ratings for Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $30.8, a high estimate of $32.00, and a low estimate of $30.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.74%. 
<img src="https://www.benzinga.com/files/images/story/2025/1751371435_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Weyerhaeuser. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hong Zhang</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$30.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Hamir Patel</td>
<td>CIBC</td>
<td>Lowers</td>
<td>Outperformer</td>
<td>$32.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Hong Zhang</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$31.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Weyerhaeuser. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Weyerhaeuser compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Weyerhaeuser's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Weyerhaeuser's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Weyerhaeuser analyst ratings.</a>
<h2>All You Need to Know About Weyerhaeuser</h2>
Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
<h3>Weyerhaeuser: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Weyerhaeuser's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -1.84% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Weyerhaeuser's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.71%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Weyerhaeuser's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.86%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Weyerhaeuser's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.5%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.54.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Weyerhaeuser Stock: Analyst Perspectives (5 Ratings)

IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) and DBmaestro, the leading enterprise-grade database DevOps platform, today announced the signing of a landmark OEM partnership agreement. This expansion will make DBmaestro's advanced database DevSecOps and observability suite available through IBM's solutions portfolio, empowering customers to achieve end-to-end DevOps automation, real-time database visibility, and unmatched agility, security, and innovation.

IBM and DBmaestro Sign OEM Partnership Agreement To Make DBmaestro's Database DevSecOps And Observability Suite Available Through IBM's Solutions Portfolio

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

SBET

SharpLink Gaming Acquires Additional 9,468 ETH

Saratoga Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) will release earnings results for the first quarter, before the opening bell on Tuesday, July 8.
Analysts expect the Florham Park, New Jersey-based company to report quarterly earnings at 72 cents per share, down from $1.05 per share in the year-ago period. Saratoga Investment projects to report quarterly revenue of $32.79 million, compared to $38.68 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 7, Saratoga Investment posted weaker-than-expected results for the fourth quarter.
Saratoga Investment shares gained 0.5% to close at $24.80 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/sar/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Compass Point analyst Casey Alexander downgraded the stock from Buy to Neutral and cut the price target from $25.25 to $24.25 on June 9, 2025. This analyst has an accuracy rate of 67%.</li>
<li>B. Riley Securities analyst Bryce Rowe reiterated a Neutral rating with a price target of $25 on Oct. 10, 2024. This analyst has an accuracy rate of 61%.</li>
</ul>
Considering buying SAR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/SAR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="639" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01041033/image-4-1024x639.png" alt="" class="wp-image-968083" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01041033/image-4-1024x639.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01041033/image-4-300x187.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01041033/image-4-768x479.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01041033/image-4.png 1082w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in"> 5 Stocks In The Spotlight: Wall Street&#8217;s Most Accurate Analysts Weigh In</a> </li>
</ul>
Photo via Shutterstock

Earnings

Top Wall Street Forecasters Revamp Saratoga Investment Expectations Ahead Of Q1 Earnings

Scotiabank analyst George Farmer downgrades INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) from Sector Outperform to Sector Underperform and lowers the price target from $23 to $0.6.

INMB

Scotiabank Downgrades INmune Bio to Sector Underperform, Lowers Price Target to $0.6

Financing

ASNS

Actelis Networks Announces Private Placement Priced At-the-Market Under Nasdaq Rules; Aggregate Gross Proceeds ~$1M

Tesla&#8217;s Chinese competitor NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) recorded a modest uptick in premarket trading on Wednesday as the electric vehicle maker unveiled its delivery figures for June<a href="https://www.benzinga.com/pressreleases/25/07/g46189280/nio-inc-provides-june-and-second-quarter-2025-delivery-update" target="_blank" rel="noreferrer noopener"> and the second quarter of 2025</a>.
NIO shipped 24,925 units in June, reflecting a 17.5% increase over the same month last year.
The update comes amid renewed political debate over electric vehicles, as former President Donald Trump took aim at Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk in a social media post.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/politics/25/06/45943245/trump-says-he-was-amazed-that-tesla-ceo-elon-musk-endorsed-him-despite-his-anti-ev-stance" rel="noreferrer noopener">Trump Says He Was &#8216;Amazed&#8217; That Tesla CEO Elon Musk Endorsed Him Despite His Anti-EV Stance</a>
Trump <a target="_blank" href="https://truthsocial.com/@realDonaldTrump/posts/114776149269773065" rel="noreferrer noopener">asserted</a>, &#8220;Electric cars are fine, but not everyone should be forced to own one,&#8221; and claimed Musk &#8220;may get more subsidy than any human being in history,&#8220; casting doubt on the long-term viability of EV growth without government support.
Meanwhile, Tesla&#8217;s Chinese peer NIO, headquartered in Shanghai, continues to ramp up its operations and diversify its product lineup to meet evolving consumer demand.
The three-month total through June reached 72,056 vehicles in the second quarter, representing a year-over-year (YoY) growth of 25.6%.
As of the end of the month, NIO&#8217;s total cumulative deliveries stood at 785,714 vehicles.
The June numbers include shipments from three distinct brands under the company&#8217;s umbrella. The flagship NIO line contributed 14,593 vehicles, while 6,400 units were delivered under the more family-centric ONVO label.
Another 3,932 units came from the company&#8217;s premium compact EV brand, FIREFLY. This diverse approach appears to be a strategic bet on catering to varying market segments and household needs.
Bolstering its brand reputation, NIO said it received top rankings in the 2025 J.D. Power studies.
The ET5 and ET5T were named leading models in the mid-size battery electric sedan category, while the EC6 earned the highest score in the premium BEV segment of the NEV-APEAL study.
This marks the seventh consecutive year NIO has topped J.D. Power&#8217;s quality rankings in its category, a testament to consistent product performance and customer approval.
The company&#8217;s latest delivery results come as a positive signal for shareholders and EV market watchers.
Steady year-over-year growth indicates NIO&#8217;s execution strength amid intensifying competition from rivals like XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) and Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>).
In a separate release, Xpeng recorded a 224% YoY increase in June deliveries as the Tesla rival delivered 197,189 units in the first half of 2025, exceeding the total units delivered <a href="https://www.benzinga.com/markets/tech/25/07/46189960/tesla-rival-xpeng-records-224-surge-in-june-deliveries-crosses-2024-sales-mark-in-6-months" target="_blank" rel="noreferrer noopener">in the entire year in 2024</a>.
Li also released its latest delivery numbers on Tuesday, reporting 36,279 vehicles delivered in June 2025. This figure represents a <a href="https://www.benzinga.com/markets/tech/25/07/46190208/li-autos-strong-q2-deliveries-mask-junes-steep-decline" target="_blank" rel="noreferrer noopener">24.1% year-over-year decrease</a>.
Price Action: NIO shares are trading higher by 0.87% to $3.460 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46121729/nio-plots-hong-kong-entry-with-new-game-plan-to-challenge-tesla" target="_blank" rel="noreferrer noopener">NIO Plots Hong Kong Entry With New Game Plan To Challenge Tesla</a></li>
</ul>
Photo via Shutterstock

Asia

Equities

Movers

Tech

General

TSLA

XPEV

NIO's June Sales Surge As Trump Casts Doubt On EV Future

As of July 1, 2025, two stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Caseys General Stores Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>)</h3>
<ul class="wp-block-list">
<li>On June 9, Caseys General Stores reported better-than-expected fourth-quarter financial results and increased its quarterly dividend. "Inside same-store sales outperformed the industry, up 2.6%, or 7.1% on a two-year stack basis, led by strong performance in hot sandwiches and bakery as well as alcoholic and non-alcoholic beverages. Our fuel team grew market share and produced a healthy margin, as fuel gross profit increased 10.7% from the prior year," said Darren Rebelez, president and CEO of Casey's General Stores. The company's stock jumped around 16% over the past month and has a 52-week high of $514.32.</li>
<li>RSI Value: 70.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CASY Price Action: Shares of Caseys gained 0.8% to close at $510.27 on Monday.</li>
<li>Edge Stock Ratings: 85.83 Momentum score with Value at 53.13. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/casy"><img loading="lazy" decoding="async" width="406" height="173" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01064654/image-1-2.png" alt="" class="wp-image-968414" style="width:312px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01064654/image-1-2.png 406w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01064654/image-1-2-300x128.png 300w" sizes="(max-width: 406px) 100vw, 406px" /></a></figure>
<h3 class="wp-block-heading">Estee Lauder Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>)</h3>
<ul class="wp-block-list">
<li>On June 13, B of A Securities upgraded the stock from Underperform to Neutral and raised its price target from $68 to $94. The company's stock gained around 21% over the past month and <a href="https://www.benzinga.com/quote/EL">has a 52-week high</a> of $108.37.</li>
<li>RSI Value: 74.4</li>
<li>EL Price Action: Shares of Estee Lauder gained 0.9% to close at $80.80 on Monday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in">5 Stocks In The Spotlight: Wall Street&#8217;s Most Accurate Analysts Weigh In</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

CASY

Top 2 Risk Off Stocks You May Want To Dump This Quarter

Press Releases

GrowGeneration Reports Fourth Quarter and Full Year 2024 Financial Results

GrowGeneration Launches B2B Pro Portal, Expanding Digital Capabilities for Commercial Cultivators and Retailers

GrowGeneration Schedules First Quarter 2025 Earnings Release Conference Call for May 8, 2025

GrowGeneration's MMI Launches Mobile Golf Bag System At Bonita Bay Club

GrowGeneration Reports First Quarter 2025 Financial Results

GrowGeneration's MMI Announces New Luxury Mobile Package & Luggage Storage Solution Designed Exclusively for Waldorf Astoria Hotels

GrowGeneration to Participate in the 25th Annual Oppenheimer Consumer Growth and E-Commerce Conference on June 9–11, 2025

GrowGeneration to Participate in the Benzinga Cannabis Capital Conference on June 8-10, 2025

GrowGeneration Acquires Viagrow, Expands into Big Box Retail and the Home Gardening Market

GrowGeneration Announces International Expansion with Distribution Agreement Across the European Union and Footprint in Costa Rica

Comments

GrowGeneration

GrowGeneration (GRWG) オプション

GrowGeneration (NASDAQ:GRWG) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル